Evidence map›Paper›PMID 30413924›Full record

ArticleRheumatology international2019

Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis.

Daniela Santos-Faria, Maxime Dougados, Laure Gossec, Serge Perrot, Anna Moltó

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Comorbid pain in axial spondyloarthritis, including fibromyalgia.Therapeutic advances in musculoskeletal disease · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Daniela Santos-FariaRheumatology Department, Unidade Local de Saúde do Alto Minho (ULSAM), Hospital Conde de Bertiandos, Largo Conde de Bertiandos, 4990-078, Ponte de Lima, Portugal. danielasantosfaria@gmail.com.ORCID 0000-0003-0211-7440
Maxime DougadosRheumatology Department, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France.
Laure GossecDepartment of Rheumatology, Pitié-Salpêtrière Hospital, Sorbonne Universités, UPMC Université, AP-HP, Paris, France.
Serge PerrotPain Center and INSERM U987, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France.
Anna MoltóRheumatology Department, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France.
Délégation Paris 5 · FRSorbonne Université · FR

Funding

MSD MSD
6 · The paper itself

Abstract

objectivesThe aim of the study is to evaluate the performance of extreme patient-reported outcomes (PRO) against definitions of fibromyalgia (FM) in patients with axial spondyloarthritis (axSpA).

methodsAncillary analysis of the Predict-SpA trial, an observational study of axSpA patients receiving TNF-α inhibitor, was performed. 'Extreme PRO' was defined as a score ≥ 8 on three out of the first five Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions (scored 0-10). FM was defined by the American College of Rheumatology (ACR) 1990 criteria and the Fibromyalgia Rapid Screening Test (FiRST). Performances of 'extreme PRO' for FM were evaluated by the sensitivity, specificity and positive likelihood ratio using the 1990 ACR criteria as gold standard. As secondary analysis, the FiRST was used as the external standard.

resultsThe prevalence of 'extreme PRO' in this population was 28.8% at baseline and decreased to 9.9% at 12 weeks. 'Extreme PRO' had low sensitivity 12 weeks after TNF initiation (0.18, 95% confidence interval [CI] 0.10-0.27 vs 0.60, 95% CI 0.50-0.71, at baseline), but high specificity (0.92, 95% CI 0.89-0.94 vs 0.78, 95% 0.74-0.82, at baseline), using ACR 1990 criteria as gold standard. Performances when tested against FiRST at 12 weeks showed higher sensitivity (0.27, 95% CI 0.20-0.35) and specificity (0.96, 95% CI 0.94-0.98).

conclusionThe proposed extreme PRO definition showed great specificity for FM recognition in patients with axSpA, suggesting it could be used in observational studies when specific items for FM classification are not available.

Indexed as

AdultAntirheumatic AgentsBiomarkersFemaleFibromyalgiaHumansMaleMiddle AgedPatient Reported Outcome MeasuresSensitivity and SpecificitySeverity of Illness IndexSpondylarthritisTumor Necrosis Factor-alphaAntirheumatic AgentsBiomarkersTumor Necrosis Factor-alphaBASDAIFibromyalgiaPatient-reported outcomesSpondyloarthritis

Identifiers

PMID30413924
OpenAlexW2899641177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.